Pyxis Oncology Inc (PYXS)

$3.46 +0.08 (2.37%)
Market Cap 209.62M
Revenue (ttm) 16.15M
Net Income (ttm) -77.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -478.82%
Debt to Equity Ratio 0.00
Volume 315,700
Avg Vol 816,020
Day's Range N/A - N/A
Shares Out 62.02M
Stochastic %K 44%
Beta 1.33
Analysts Strong Sell
Price Target $6.00

Company Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 453 3596
Address:
321 Harrison Avenue, 11th Floor, Suite 1, Boston, United States
biohuntress
biohuntress Oct. 22 at 3:11 PM
$PYXS ESMO- Key Findings from the Presentations Mechanism of Action: MICVO employs a unique extracellular-cleaving method, differing from traditional ADCs, which usually target cell surfaces and internalize inside the cells. Therapeutic Benefits: Direct Tumor Cell Killing: Evidence showed that MICVO directly affects tumor cells. Bystander Killing: The drug aids in killing adjacent cancer cells. Immunogenic Cell Death: Findings highlighted evidence that MICVO activates immune responses against tumors. Clinical Observations: Notable reductions were observed in circulating tumor DNA (ctDNA) in the majority of samples assessed, particularly in head and neck squamous cell carcinoma (HNSCC) cases. Pyxis Oncology's presence at ESMO 2025 marks a critical moment in expanding the understanding and application of MICVO in oncology.
1 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 21 at 3:06 PM
$PYXS heating up again ... still in it
0 · Reply
Stockprofiler
Stockprofiler Oct. 20 at 5:48 PM
$CRDL Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics October 15, 2025 — @ZacksResearch For Immediate Release Chicago, IL – October 15, 2025 – Zacks Equity Research discusses Akebia Therapeutics $AKBA, Ironwood Pharmaceuticals $IRWD, Pyxis Oncology $PYXS, Cardiol Therapeutics $CRDL and Plus Therapeutics $PSTV. Industry: Drugs (non-Big Pharma) Link: https://zacks.com/commentary/2767977/5-small-drug-stocks-to-buy-as-the-industry-shows-some-recovery
0 · Reply
Hawaiiansurf1
Hawaiiansurf1 Oct. 19 at 3:10 AM
$PYXS Data is better than CRBP. 50% ORR and 100% stopping all progression. Waiting on bigger Sample Size. Will SKYROCKET with upcoming results.
1 · Reply
Bainv
Bainv Oct. 18 at 6:24 PM
$PYXS CRBP's data bad for PYXS? need to have better ORR.
0 · Reply
FinJay
FinJay Oct. 15 at 1:59 PM
🚨 5 Short Squeeze Stocks About to Rip! 🔥 Massive Naked Shorting Exposed 👀 Big moves could be coming soon — don’t miss this breakdown ⬇️ $CRML $BJDX $ELBM $PYXS $DPRO 📺 https://youtu.be/1cmFwhOhgt4
0 · Reply
St0ckman691
St0ckman691 Oct. 14 at 5:11 PM
$CRDL makes the list of 5 Small Drug Stocks to Buy as the Industry Shows Some Recovery: $AKBA $IRWD $PYXS $PSTV https://finance.yahoo.com/news/5-small-drug-stocks-buy-145700720.html
1 · Reply
Power2k
Power2k Oct. 14 at 3:23 PM
$PYXS $GMAB acquired $MRUS for 8B mostly due to Merus' promising Head & Neck cancer (HNSCC) trial data. Pyxis has a matched or even a bit superior HNSCC data than Merus', and it sits only at 200M cap. Extremely undervalued.
0 · Reply
biohuntress
biohuntress Oct. 13 at 8:09 PM
$PYXS ESMO https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-present-translational-data-and-key-biology
0 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 13 at 4:50 PM
$PYXS waking up
0 · Reply
Latest News on PYXS
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

Oct 13, 2025, 4:05 PM EDT - 12 days ago

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

Oct 9, 2025, 7:30 AM EDT - 16 days ago

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 30, 2025, 4:24 PM EDT - 25 days ago

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology to Participate in September Investor and Industry Conferences

Aug 21, 2025, 7:30 AM EDT - 2 months ago

Pyxis Oncology to Participate in September Investor and Industry Conferences

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 4:05 PM EDT - 2 months ago

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 7:00 AM EDT - 5 months ago

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

May 14, 2025, 7:30 AM EDT - 5 months ago

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Apr 25, 2025, 1:17 PM EDT - 6 months ago

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 7:30 AM EDT - 7 months ago

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 7 months ago

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 7:30 AM EDT - 7 months ago

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Mar 3, 2025, 7:30 AM EST - 8 months ago

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Feb 26, 2025, 7:30 AM EST - 8 months ago

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Feb 4, 2025, 7:30 AM EST - 9 months ago

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Dec 19, 2024, 4:08 PM EST - 11 months ago

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Dec 7, 2024, 1:30 AM EST - 11 months ago

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Nov 21, 2024, 9:18 AM EST - 1 year ago

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Nov 20, 2024, 4:05 PM EST - 1 year ago

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Nov 8, 2024, 1:30 PM EST - 1 year ago

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Moment Of Truth Approaches For Pyxis Oncology

Sep 13, 2024, 7:08 AM EDT - 1 year ago

Moment Of Truth Approaches For Pyxis Oncology

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Jun 10, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

May 30, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

May 14, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

May 9, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Mar 27, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Mar 21, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Mar 7, 2024, 4:30 PM EST - 1 year ago

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Mar 5, 2024, 4:45 PM EST - 1 year ago

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Nov 7, 2023, 4:30 PM EST - 2 years ago

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Sep 27, 2023, 9:18 AM EDT - 2 years ago

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed

Sep 7, 2023, 8:09 AM EDT - 2 years ago

Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Aug 31, 2023, 4:01 PM EDT - 2 years ago

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Aug 23, 2023, 8:35 AM EDT - 2 years ago

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Aug 10, 2023, 2:56 PM EDT - 2 years ago

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

Jul 10, 2023, 3:01 AM EDT - 2 years ago

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

Pyxis: Unique ADC Approach With A Catalyst In Late 2023

Jun 15, 2023, 8:20 AM EDT - 2 years ago

Pyxis: Unique ADC Approach With A Catalyst In Late 2023

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

Jun 12, 2023, 2:59 AM EDT - 2 years ago

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

May 30, 2023, 10:52 PM EDT - 2 years ago

APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

May 30, 2023, 8:30 AM EDT - 2 years ago

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

Pyxis Oncology to Acquire Apexigen

May 24, 2023, 6:45 AM EDT - 2 years ago

Pyxis Oncology to Acquire Apexigen

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

May 11, 2023, 7:00 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

Pyxis Oncology: Cashed Up And Entering The Clinic

Mar 27, 2023, 7:32 AM EDT - 2 years ago

Pyxis Oncology: Cashed Up And Entering The Clinic

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

Mar 22, 2023, 6:45 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

biohuntress
biohuntress Oct. 22 at 3:11 PM
$PYXS ESMO- Key Findings from the Presentations Mechanism of Action: MICVO employs a unique extracellular-cleaving method, differing from traditional ADCs, which usually target cell surfaces and internalize inside the cells. Therapeutic Benefits: Direct Tumor Cell Killing: Evidence showed that MICVO directly affects tumor cells. Bystander Killing: The drug aids in killing adjacent cancer cells. Immunogenic Cell Death: Findings highlighted evidence that MICVO activates immune responses against tumors. Clinical Observations: Notable reductions were observed in circulating tumor DNA (ctDNA) in the majority of samples assessed, particularly in head and neck squamous cell carcinoma (HNSCC) cases. Pyxis Oncology's presence at ESMO 2025 marks a critical moment in expanding the understanding and application of MICVO in oncology.
1 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 21 at 3:06 PM
$PYXS heating up again ... still in it
0 · Reply
Stockprofiler
Stockprofiler Oct. 20 at 5:48 PM
$CRDL Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics October 15, 2025 — @ZacksResearch For Immediate Release Chicago, IL – October 15, 2025 – Zacks Equity Research discusses Akebia Therapeutics $AKBA, Ironwood Pharmaceuticals $IRWD, Pyxis Oncology $PYXS, Cardiol Therapeutics $CRDL and Plus Therapeutics $PSTV. Industry: Drugs (non-Big Pharma) Link: https://zacks.com/commentary/2767977/5-small-drug-stocks-to-buy-as-the-industry-shows-some-recovery
0 · Reply
Hawaiiansurf1
Hawaiiansurf1 Oct. 19 at 3:10 AM
$PYXS Data is better than CRBP. 50% ORR and 100% stopping all progression. Waiting on bigger Sample Size. Will SKYROCKET with upcoming results.
1 · Reply
Bainv
Bainv Oct. 18 at 6:24 PM
$PYXS CRBP's data bad for PYXS? need to have better ORR.
0 · Reply
FinJay
FinJay Oct. 15 at 1:59 PM
🚨 5 Short Squeeze Stocks About to Rip! 🔥 Massive Naked Shorting Exposed 👀 Big moves could be coming soon — don’t miss this breakdown ⬇️ $CRML $BJDX $ELBM $PYXS $DPRO 📺 https://youtu.be/1cmFwhOhgt4
0 · Reply
St0ckman691
St0ckman691 Oct. 14 at 5:11 PM
$CRDL makes the list of 5 Small Drug Stocks to Buy as the Industry Shows Some Recovery: $AKBA $IRWD $PYXS $PSTV https://finance.yahoo.com/news/5-small-drug-stocks-buy-145700720.html
1 · Reply
Power2k
Power2k Oct. 14 at 3:23 PM
$PYXS $GMAB acquired $MRUS for 8B mostly due to Merus' promising Head & Neck cancer (HNSCC) trial data. Pyxis has a matched or even a bit superior HNSCC data than Merus', and it sits only at 200M cap. Extremely undervalued.
0 · Reply
biohuntress
biohuntress Oct. 13 at 8:09 PM
$PYXS ESMO https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-present-translational-data-and-key-biology
0 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 13 at 4:50 PM
$PYXS waking up
0 · Reply
Relee187200
Relee187200 Oct. 13 at 3:09 PM
$PYXS What happened?!
2 · Reply
Bullbear1010101
Bullbear1010101 Oct. 10 at 10:57 PM
$PYXS looks stable even with market down around 3 percent ..lost about .12 only today too high for me to rebuy
0 · Reply
smoketuna
smoketuna Oct. 10 at 10:21 AM
$PYXS 83% with 🎯 TunaSignal.ai score! while price $2.X.14 - Catch the Big Movers Before They Break Out - Powered by AI
0 · Reply
stockchacing
stockchacing Oct. 10 at 5:05 AM
$PYXS amazing performance 😎! Next one to skyrocket will be $SLS ! FCK Cancer!!
0 · Reply
StockScanners
StockScanners Oct. 10 at 2:17 AM
$PYXS reached 3.93. come on team lets go!
0 · Reply
StockScanners
StockScanners Oct. 10 at 1:45 AM
$PYXS keep watch if this holds above 3.60
0 · Reply
JacksofAmerica
JacksofAmerica Oct. 10 at 12:19 AM
$PYXS made a decent purchase of this stock at $1.07 i has no idea it would jump this quickly. Wish i put more down 😄
0 · Reply
stocksrtoohard
stocksrtoohard Oct. 9 at 10:55 PM
$PYXS was pretty close to one of the best trades ive ever made off gut instinct and basic price action that ive studied for 2-3y+. here is the timeline; inverted h&s on 30m/1h/4h breakout and hold of $2.55 (harsh retests on the way). been clear break since and may be re-entering to a pos. again soon if a pullback presents itself properly (drop some pos placement if any). took my final pay on pos. at $3.10-3.20 (~450% gained in total). didn’t want to risk little volume not being able to push through the gap. hope everyone made some bread and continues to if she keeps ripping 🤘🏽
0 · Reply
Hawaiiansurf1
Hawaiiansurf1 Oct. 9 at 9:49 PM
$PYXS Genmab bought Pyxix competition Merus for 8 Billion ($97 share). Pyxis has superior MOA (Mechanism of Action). We skyrocket with Good results!
0 · Reply
IntraTrades
IntraTrades Oct. 9 at 9:48 PM
$NUAI 81.41% $JFU 51.62% $PYXS 31.62% $LAES 31.53%
0 · Reply
stockchacing
stockchacing Oct. 9 at 8:03 PM
$SLS normally this stock should be performing like this little one $PYXS ! Really impressive , hope to see the same and better soon for our SLS family! Good night from Switzerland!
0 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 9 at 7:55 PM
$FLUX $PYXS $LAES LFG BABY
0 · Reply